Interações medicamentosas
Amlodipine-atorvastatin + Apalutamide
Gravidade: Grave
Amlodipine-atorvastatin and Apalutamide: major interaction.
Última atualização
Para profissionais de saúde — apenas referência. Esta página é um resumo breve, não é aconselhamento médico nem substitui a bula oficial ou o julgamento clínico. Verifique sempre antes de prescrever ou dispensar.
O conteúdo clínico desta página está disponível apenas em inglês.
Resumo
Apalutamide is a strong CYP3A4 inducer and can substantially lower exposure to amlodipine and atorvastatin, both CYP3A4 substrates. This may lead to loss of blood pressure control and reduced lipid-lowering efficacy. The induction effect develops over days to weeks and persists after apalutamide is stopped.
O que esta interação significa em palavras simples
Amlodipine-atorvastatin and Apalutamide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Amlodipine-atorvastatin belongs to Cardiovascular; Apalutamide belongs to Endocrine.
Por que acontece
Induction of CYP3A4 (and related transporters) by apalutamide increases the metabolism of amlodipine and atorvastatin.
O que fazer
Monitor blood pressure and LDL cholesterol, and increase doses of amlodipine or atorvastatin if needed, or switch to a less CYP3A4-dependent agent. Reassess doses after apalutamide is discontinued.
O que perguntar ao farmacêutico
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Para assinantes do Pro+
Desbloqueie a página completa
Crie uma conta e comece um teste do Pro+ para desbloquear a orientação completa de conduta para Amlodipine-atorvastatin e Apalutamide, as notas adicionais, os detalhes da evidência e o verificador de interações para uma prescrição completa.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Experimente o Pro+ grátis por 7 dias na web. Sem cartão.
Outras interações de Amlodipine-atorvastatin
Outras interações de Apalutamide
- Apalutamide + Cabotegravir Contraindicada
- Apalutamide + Cobicistat Contraindicada
- Apalutamide + Doravirine Contraindicada
- Apalutamide + Elbasvir / grazoprevir Contraindicada
- Apalutamide + Ensitrelvir Contraindicada
- Apalutamide + Fostemsavir Contraindicada
Perguntas frequentes
Can I take Amlodipine-atorvastatin with Apalutamide?
MediHelp rates the interaction as major. Amlodipine-atorvastatin and Apalutamide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Apalutamide is a strong CYP3A4 inducer and can substantially lower exposure to amlodipine and atorvastatin, both CYP3A4 substrates. This may lead to loss of blood pressure control and reduced lipid-lowering efficacy. The induction effect develops over days to weeks and persists after apalutamide is stopped.
How serious is the interaction between Amlodipine-atorvastatin and Apalutamide?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood pressure and LDL cholesterol, and increase doses of amlodipine or atorvastatin if needed, or switch to a less CYP3A4-dependent agent. Reassess doses after apalutamide is discontinued.
What other medicines interact with Amlodipine-atorvastatin?
MediHelp also lists interactions of Amlodipine-atorvastatin with, for example, Amifostine, Atazanavir, Clarithromycin. The full list is on the Amlodipine-atorvastatin page.
Monografias completas, posologia e verificador de interações no app MediHelp
Abra a referência completa, verifique interações entre vários medicamentos e use as ferramentas de posologia no app MediHelp.
